Biolase, Inc. · OTC:BIOLQ

Biolase — Investor Presentation (January 2014)

33 slides from Biolase's investor presentation, Jan 14, 2014

  1. Slide 1: BIOLASE Investor Update January 2014

    BIOLASE, Inc. Federico Pignatelli, Chairman and CEO Alexander K. Arrow, President and COO NASDAQ: BIOL www.biolase.com Investor Update January 2014 Exhibit 99.1

  2. Slide 2: The Total Technology Solution from BIOLASE

    DIAGNOSIS: The BEST 2D & 3D Imaging. RESTORATION: The BEST digital impressions. DESIGN: The BEST design tools. MILLING: The BEST chair- side milling. TREATMENT: The BEST laser technology. THE TOTAL TECHNOLOGY SOLUTION FROM BIOLASE

  3. Slide 3: With WaterLase, BIOLASE has invented, developed, patented

    With WaterLase, BIOLASE has: Invented, Developed, Patented, and Been granted FDA clearance for a fundamentally different kind of revolutionary tissue-cutting tool.

  4. Slide 4: Water molecules in tissue absorb laser energy

    Water molecules in tissue absorb laser energy from WaterLase and vaporize, resulting in an atraumatic ablation of the tissue. – Very little trauma or bleeding, – No heat or vibration, and – Little or no pain – Significantly reduces cross contamination WaterLase All-Tissue Lasers Extensive patent pro

  5. Slide 5: Patient Testimony

    Patient Testimony

  6. Slide 6: How It Works: WaterLase High Speed Cutting

    How It Works: WaterLase High Speed Cutting

  7. Slide 7: WaterLase Atraumatic Pediatric Tooth Extraction

    WaterLase Atraumatic Pediatric Tooth Extraction The aiming beam does not cut the tissue nor generate heat. The tissue is cut biologically, with little or no pain, when the laser energizes water at the molecular level.

  8. Slide 8: BIOLASE Evolution

    BIOLASE Evolution BIOLASE

  9. Slide 9: Other Hard Tissue Laser Systems compared to the Waterlase iPlus

    Other Hard Tissue Laser Systems compared to the Waterlase iPlus Waterlase iPlus Fiber Delivery Fotona Lightwalker Articulated Arm Er:YSGG, Latest Technology Er:YAG, 25-year old Technology An articulated arm is awkward to use Fiber delivery is ergonomic and natural for the dentist to use

  10. Slide 10: Laser Products

    Soft-tissue medical lasers: The EPIC-S (surgical & ENT) and EPIC-V (veterinary). Soft-tissue dental diode lasers: The EPIC Soft Tissue laser, which in June 2013 won the MDE gold medal in medical device design, and the iLase, a portable diode laser with no foot pedal, power cord, or external controls

  11. Slide 11: Digital Radiography and CAD/CAM Products

    Digital Radiography and CAD/CAM Products NewTom 3D CBCT cone beam: Medical grade imaging technology. Less cost, less radiation exposure. Exclusive U.S. & Canada distribution agreement through Feb 2015. TRIOS CAD/CAM intra - oral scanner: Digital impression taking. Hand held scanner, operator's contr

  12. Slide 12: The Galaxy BioMill

    The Galaxy BioMill completes the CAD/CAM segment of BIOLASE’s Total Technology Solution. GALAXY BioMill System

  13. Slide 13: Chair-Side Milling Market

    A $500 million market in 2013, growing at approximately 20% Historical CAD/CAM Systems for the Dental Office are Obsolete compared with Laptop Scanners and Tabletop Milling Modules Chair-Side Milling Market

  14. Slide 14: GALAXY BioMill System

    GALAXY BioMill System Developed in conjunction with imes- icore and 3Shape. Open architecture. Introduced at the Greater NY Dental Meeting in December 2013. Expected to be ready to ship by end of Q1 or beginning of Q2 2014. High quality at two-thirds the price of the industry leader in a $500M annua

  15. Slide 15: Feature Comparison: GALAXY BioMill System

    Feature Comparison: GALAXY BioMill System

  16. Slide 16: Why Should Dentists Buy a WaterLase iPlus?

    Monthly Finance Payment New Monthly Revenue Generated Why Should Dentists Buy a WaterLase iPlus? Approx. $1,300 $5,000 – $15,000 A dentists’ return on investment can be 500% to 1,500% Return on Investment WaterLase enables dentists to perform procedures that they would otherwise refer to specialists

  17. Slide 17: Value Proposition of WaterLase

    WaterLase dentists offer their patients more procedures and they have a higher rate of acceptance from their patients. This is because patients are more likely to accept treatment when it does not hurt them. Case Study: Doctor David Peck (Springfield, MA) – Practice running at approximately $1M per

  18. Slide 18: BIOLASE

    BIOLASE

  19. Slide 19: Telephone versus Smart Phone

    Telephone Smart Phone Telephone versus Smart Phone Phone calls Phone calls Texting Web browsing Navigation Photos and videos Scheduling

  20. Slide 20: Conventional Dental Drill versus WaterLase

    Dental Drill Waterlase Conventional Dental Drill versus WaterLase Cutting (hard tissue) Cutting (hard and soft tissue) Polishing Surface modification Coagulation Disinfection Bio stimulation Desensitization -

  21. Slide 21: Scalpel versus the EPIC diode

    Scalpel Epic Laser Scalpel versus the EPIC diode Cutting Cutting Teeth whitening Coagulation Disinfection Bio stimulation Desensitization -

  22. Slide 22: Annual Net Revenue and Stock Price

    Annual Net Revenue and Stock Price $20 $15 $10 $5 Projected revenue guidance of $57-$59 million, last updated November 12, 2013. $ - $10,000 $20,000 $30,000 $40,000 $50,000 $60,000 $70,000 $80,000 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013

  23. Slide 23: Quarterly Net Revenue and Influencers in Turnaround

    Quarterly Net Revenue and Influencers in Turnaround Launched Cefla’s NewTom Cone Beam Imaging products Introduced iLase hand-held soft- tissue diode laser Launched WaterLase ® iPlus™ all-tissue laser Launched 3Shape’s TRIOS™ intra-oral scanner CE Mark & FDA clearance for EPIC 10 New management with

  24. Slide 24: Filling our Open Territories

    Filling our Open Territories 3Q 2013 1Q 2014

  25. Slide 25: BIOLASE's Market Opportunity

    160,000 dentists in US & Canada. Approximately 1.5 M dentists – rapid growth in emerging economies. Current market penetration. – approx. 3%-5% of dental practices in US. – approx. 1% worldwide. Each incremental 1% market penetration is $600M revenue. Dental laser market opportunity may > $50B in 20

  26. Slide 26: Dominant Market Position

    80% 45% Dominant Market Position WW Hard-tissue Dental Laser Market WW Total Dental Laser Market BIOLASE Market Share

  27. Slide 27: Otolaryngology (ENT) opportunity

    Otolaryngology (ENT) opportunity 9,000 otolaryngologists in the U.S. 700,000 nasal turbinate reductions per year 30% of them need revisions 600,000 sinuloplasties per year The EPIC-S is the most precise, ergonomic, and newest laser available for otolaryngologists Launched in 4Q 2013

  28. Slide 28: Veterinary opportunity

    Veterinary opportunity 52,000 veterinarians in the U.S. The EPIC-V is a versatile tool for veterinary dental, dermatological, and surgical procedures on virtually every mammalian and bird species In use by KOL veterinarians Launched in 3Q 2013

  29. Slide 29: WaterLase Technology Substantially Reduces Risk of Cross Contamination

    WaterLase Technology Substantially Reduces the Risk of Cross Contamination and Contagion Burs and Endo Files: WaterLase Tips: • Complex and rugged bur surface difficult to sterilize. • Smooth tip surface does not harbor debris or bacteria like abrasive surface of burs or files. • YSGG laser energy i

  30. Slide 30: Changing Attitudes Toward Cross-Contamination

    Changing Attitudes Toward Cross-Contamination Cross-Contamination beginning to appear in mainstream dental ads to dentists Expected that this will soon begin targeted to patients as well

  31. Slide 31: Extensive Patent Portfolio

    Issued & Active Pending Total Over 310 patents issued & pending. 70% are related to WaterLase technology & medical lasers. Extensive Patent Portfolio U.S. International Total

  32. Slide 32: BIOLASE Facilities & Employees

    BIOLASE Corporate Headquarters in Irvine, California Sales offices in Floss (Germany), Madrid (Spain), Shanghai (China), and Mumbai (India); expansion planned in Dubai (UAE), and Rio de Janero (Brazil). Floss also has service and manufacturing capabilities. Training facilities through the United Sta

  33. Slide 33: Management and Board of Directors

    Federico Pignatelli, Chairman Alexander Arrow, MD Samuel Low, DDS Frederic Moll, MD Norman Nemoy, MD Jim Talevich Management and Board of Directors Management Board of Directors Federico Pignatelli, CEO Salary $1, ownership position 5.5% Alexander Arrow, President & COO Ownership position: 1.5% Fred

Biolase — Investor Presentation (January 2014) on 6ix